The role of immunotherapy in Guillain-Barré syndrome: Understanding the mechanism of action

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 10, 2011, Pages 1551-1560

  Shahrizaila, Nortina ^a   Yuki, Nobuhiro ^b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

acute autoimmune neuropathies; Guillain Barr syndrome; immunotherapy; pathogenesis

Indexed keywords

AUTOANTIGEN; CORTICOSTEROID; GANGLIOSIDE GQ 1B ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN D ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G1B ANTIBODY; METHYLPREDNISOLONE; PLACEBO; UNCLASSIFIED DRUG;

ACUTE INFLAMMATORY DEMYELINATING NEUROPATHY; ACUTE MOTOR AXONAL NEUROPATHY; BICKERSTAFF BRAINSTEM ENCEPHALITIS; CAMPYLOBACTER JEJUNI; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DISABILITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENCEPHALITIS; GUILLAIN BARRE SYNDROME; HAEMOPHILUS MENINGITIS; HEMODYNAMICS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MACROPHAGE; NERVE CELL DEGENERATION; NERVE FIBER MEMBRANE; NEUROPATHY; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PLASMAPHERESIS; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMYELINIZATION; REVIEW; RISK REDUCTION; TREATMENT DURATION;

ANIMALS; COMBINED MODALITY THERAPY; GLUCOCORTICOIDS; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; PLASMA EXCHANGE; SEVERITY OF ILLNESS INDEX;

EID: 79958760929     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.564160     Document Type: Review

References (97)

1. Hovi T, Stenvik M. Surveillance of patients with acute flaccid paralysis in Finland: report of a pilot study. Bull World Health Organ 2000;12:298-304 (Pubitemid 30208320)
2. Olive JM, Castillo C, Castro RG, de Quadros CA. Epidemiologic study of Guillain-Barre syndrome in children < 15 years of age in Latin America. J Infect Dis 1997;175(Suppl 1): S160-4 (Pubitemid 27053503)
3. Guillain G, Barre JA, Strohl A. Sur un syndrome de radiculonevrite avec hyperalbuminose du liquide cephalo-rachidien sans reaction cellulaire: remarques sur les caracteres cliniques et graphiques des reflexes tendineux. Bulletins et memoires de la Societe des Medecins des Hopitaux de Paris 1916;40:1462-70
4. van Koningsveld R, van Doorn PA, Schmitz PI, et al. Mild forms of Guillain-Barre syndrome in an epidemiologic survey in the Netherlands. Neurology 2000;54:620-5 (Pubitemid 30082928)
5. Govoni V, Granieri E. Epidemiology of the Guillain-Barre syndrome. Curr Opin Neurol 2001;14:605-13
6. Chio A, Cocito D, Leone M, et al. Guillain-Barre syndrome: a prospective, population-based incidence and outcome survey. Neurology 2003;60:1146-50 (Pubitemid 36418776)
7. Bogliun G, Beghi E. Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. Acta Neurol Scand 2004;110:100-6 (Pubitemid 39044046)
8. Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996;40:635-44 (Pubitemid 26357889)
9. Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996;39:625-35 (Pubitemid 26143601)
10. Ho TW, Mishu B, Li CY, et al. Guillain-Barre syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118:597-605
11. Hadden RDM, Cornblath DR, Hughes RAC, et al.; Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Ann Neurol 1998;44:780-8 (Pubitemid 28516049)
12. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993;33:333-42 (Pubitemid 23103964)
13. Ogawara K, Kuwabara S, Mori M, et al. Axonal Guillain-Barre syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000;48:624-31
14. Paradiso G, Tripoli J, Galicchio S, Fejerman N. Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barre syndrome: a reappraisal. Ann Neurol 1999;46:701-7 (Pubitemid 29518130)
15. Kalita J, Misra UK, Das M. Neurophysiological criteria in the diagnosis of different clinical types of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2008;79:289-93 (Pubitemid 351303384)
16. Kushnir M, Klein C, Pollak L, Rabey JM. Evolving pattern of Guillain-Barre syndrome in a community hospital in Israel. Acta Neurol Scand 2008;117:347-50 (Pubitemid 351506434)
17. Islam Z, Jacobs BC, van Belkum A, et al. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh. Neurology 2010;74:581-7
18. Kokubun N, Nishibayashi M, Uncini A, et al. Conduction block in acute motor axonal neuropathy. Brain 2010;133:2897-908
19. Uncini A, Yuki N. Electrophysiologic and immunopathologic correlates in Guillain-Barre syndrome subtypes. Expert Rev Neurother 2009;9:869-84
20. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956;255:57-65
21. Bickerstaff ER. Brain-stem encephalitis; further observations on a grave syndrome with benign prognosis. Br Med J 1957;1:1384-7
22. Bickerstaff ER, Cloake PC. Mesencephalitis and rhombencephalitis. Br Med J 1951;2:77-81
23. Ito M, Kuwabara S, Odaka M, et al. Bickerstaffs brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J Neurol 2008;255:674-82
24. Odaka M, Yuki N, Yamada M, et al. Bickerstaffs brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barre syndrome. Brain 2003;126:2279-90 (Pubitemid 37432371)
25. Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology. Guillain-Barre syndrome variants in Emilia-Romagna, Italy, 1992-3: incidence, clinical features, and prognosis. J Neurol Neurosurg Psychiatry 1998;65:218-24
26. Lyu RK, Tang LM, Cheng SY, et al. Guillain-Barre syndrome in Taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry 1997;63:494-500
27. Mori M, Kuwabara S, Fukutake T, et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001;56:1104-6 (Pubitemid 32336323)
28. Hughes RAC, Swan AV, Raphael JC, et al. Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain 2007;130:2245-57 (Pubitemid 47327619)
29. Jacobs BC, Rothbarth PH, van der Meche FGA, et al. The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology 1998;51:1110-15 (Pubitemid 28473409)
30. Winer JB, Hughes RAC, Anderson MJ, et al. A prospective study of acute idiopathic neuropathy: II. antecedent events. J Neurol Neurosurg Psychiatry 1988;51:613-18
31. Rees JH, Soudain SE, Gregson NA, Hughes RAC. Campylobacter jejuni infection and Guillain-Barre syndrome. N Engl J Med 1995;333:1374-9
32. Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect Dis 2001;1:29-37 (Pubitemid 33586038)
33. Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci USA 2004;101:11404-9 (Pubitemid 39038359)
34. Yuki N, Sato S, Inuzuka T, et al. Axonal degeneration in the Guillain-Barre syndrome and anti-GM1 ganglioside antibodies. Muscle Nerve 1992;15:116
35. Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 1990;40:1900-2
36. Kusunoki S, Chiba A, Kon K, et al. N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barre syndrome. Ann Neurol 1994;35:570-6
37. Kusunoki S, Iwamori M, Chiba A, et al. GM1b is a new member of antigen for serum antibody in Guillain-Barre syndrome. Neurology 1996;47:237-42 (Pubitemid 26243890)
38. Kuwabara S, Ogawara K, Misawa S, et al. Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barre syndrome? Neurology 2004;63:529-33 (Pubitemid 39031386)
39. Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. J Exp Med 1993;178:1771-5 (Pubitemid 23318456)
40. Koga M, Gilbert M, Takahashi M, et al. Comprehensive analysis of bacterial risk factors for the development of Guillain-Barre syndrome after Campylobacter jejuni enteritis. J Infect Dis 2006;193:547-55 (Pubitemid 43202746)
41. Susuki K, Nishimoto Y, Yamada M, et al. Acute motor axonal neuropathy rabbit model: immune attack on nerve root axons. Ann Neurol 2003;54:383-8 (Pubitemid 37072042)
42. Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 2001;49:712-20 (Pubitemid 32530237)
43. Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barre syndrome. N Engl J Med 1995;333:1374-9
44. Shahrizaila N, Yuki N. Guillain-Barre syndrome animal model: the first proof of molecular mimicry in human autoimmune disorder. J Biomed Biotechnol 2011;2011:829129 15 December 2010 [Epub ahead of print]
45. Susuki K, Rasband MN, Tohyama K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007;27:3956-67 (Pubitemid 46597169)
46. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992;31:677-9
47. Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911-17 (Pubitemid 23318855)
48. Willison HJ, Veitch J. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J Neuroimmunol 1994;50:159-65
49. Yuki N, Sato S, Tsuji S, et al. An immunologic abnormality common to Bickerstaffs brain stem encephalitis and Fishers syndrome. J Neurol Sci 1993;118:83-7 (Pubitemid 23269971)
50. Koga M, Ang CW, Yuki N, et al. Comparative study of preceding Campylobacter jejuni infection in Guillain-Barre syndrome in Japan and The Netherlands. J Neurol Neurosurg Psychiatry 2001;70:693-5 (Pubitemid 32398012)
51. Koga M, Gilbert M, Li J, et al. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology 2005;64:1605-11 (Pubitemid 40617699)
52. Kimoto K, Koga M, Odaka M, et al. Relationship of bacterial strains to clinical syndromes of Campylobacter-associated neuropathies. Neurology 2006;67:1837-43 (Pubitemid 44900763)
53. Houliston RS, Koga M, Li J, et al. A Haemophilus influenzae strain associated with Fisher syndrome expresses a novel disialylated ganglioside mimic. Biochemistry 2007;46:8164-71 (Pubitemid 47051652)
54. Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911-17 (Pubitemid 23318855)
55. Liu JX, Willison HJ, Pedrosa-Domellof F. Immunolocalisation of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest Ophthalmol Vis Sci 2009;50(7):3226-32 28 Feb 2009 [Epub ahead of print]
56. Kuwabara S, Asahina M, Nakajima M, et al. Special sensory ataxia in Miller Fisher syndrome detected by postural body sway analysis. Ann Neurol 1999;45:533-6 (Pubitemid 29165824)
57. Yuki N. Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome). J Neuroimmunol 2009;215:1-9
58. Hughes RAC, Swan AV, van Doorn PA. Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev 2010:CD001446
59. Guillain-Barre Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barre syndrome. Lancet 1993;341:586-90
60. van Koningsveld R, Schmitz PI, van der Meche FGA, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet 2004;363:192-6 (Pubitemid 38114716)
61. Susuki K, Yuki N. Effect of methylprednisolone in patients with Guillain-Barre syndrome. Lancet 2004;363:1236-7; author reply 1237-8
62. Rubinstein MA, Kagan BM, Macgillviray MH, et al. Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions. Ann Intern Med 1959;51:1409-19
63. Brettle RP, Gross M, Legg NJ, et al. Treatment of acute polyneuropathy by plasma exchange. Lancet 1978;2:1100 (Pubitemid 9052892)
64. Gross ML, Legg NJ, Lockwood MC, Pallis C. The treatment of inflammatory polyneuropathy by plasma exchange. J Neurol Neurosurg Psychiatry 1982;45:675-9 (Pubitemid 12039865)
65. Server AC, Lefkowith J, Braine H, McKhann GM. Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange. Ann Neurol 1979;6:258-61 (Pubitemid 9253597)
66. Rumpl E, Mayr U, Gerstenbrand F, et al. Treatment of Guillain-Barre syndrome by plasma exchange. J Neurol 1981;225:207-17 (Pubitemid 11070496)
67. The Guillain-Barre syndrome Study Group. Plasmapheresis and acute Guillain-Barre syndrome. Neurology 1985;35:1096-104
68. The French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. Ann Neurol 1987;22:753-61
69. The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Appropriate number of plasma exchanges in Guillain-Barre syndrome. Ann Neurol 1997;41:298-306
70. Yuki N, Tagawa Y, Hirata K. Minimal number of plasma exchanges needed to reduce immunoglobulin in Guillain-Barre syndrome. Neurology 1998;51:875-7 (Pubitemid 28449278)
71. Greenshields KN, Halstead SK, Zitman FM, et al. The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J Clin Invest 2009;119:595-610
72. Goodfellow JA, Bowes T, Sheikh K, et al. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J Neurosci 2005;25:1620-8 (Pubitemid 40279266)
73. Lehmann HC, Lopez PH, Zhang G, et al. Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model. J Neurosci 2007;27:27-34 (Pubitemid 46089956)
74. Lopez G, Zhang J, Zhang HC, et al. Passive transfer of IgG anti-GM1 antibodies impairs peripheral nerve repair. J Neurosci 2010;30:9533-41
75. Cornblath DR, Hughes RAC. Treatment for Guillain-Barre syndrome. Ann Neurol 2009;66:569-70
76. Kleyweg RP, van der Meche FGA, Meulstee J. Treatment of Guillain-Barre syndrome with high-dose gammaglobulin. Neurology 1988;38:1639-41
77. van der Meche FGA, Schmitz PI, Dutch Guillain-Barre Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 1992;326:1123-9
78. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet 1997;349:225-30
79. Korinthenberg R, Monting JS. Natural history and treatment effects in Guillain-Barre syndrome: a multicentre study. Arch Dis Child 1996;74:281-7, Apr 1996
80. Gurses N, Uysal S, Cetinkaya F, et al. Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome. Scand J Infect Dis 1995;27:241-3
81. Korinthenberg R, Schessl J, Kirschner J, Monting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome: a randomized trial. Pediatrics 2005;116:8-14
82. Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC. Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 2001;71:235-8 (Pubitemid 32675152)
83. Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome. Ann Neurol 2009;66:597-603
84. Jacobs BC, van Doorn PA, Schmitz PI, et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barre syndrome. Ann Neurol 1996;40:181-7
85. Kuwabara S, Mori M, Ogawara K, et al. Intravenous immunoglobulin therapy for Guillain-Barre syndrome with IgG anti-GM1 antibody. Muscle Nerve 2001;24:54-8 (Pubitemid 32038027)
86. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004;291:2367-75 (Pubitemid 38656304)
87. Nishimoto Y, Koga M, Kamijo M, et al. Immunoglobulin improves a model of acute motor axonal neuropathy by preventing axonal degeneration. Neurology 2004;62:1939-44 (Pubitemid 38738200)
88. Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann Neurol 2002;51:673-80 (Pubitemid 34568844)
89. Zhang G, Lopez PH, Li CY, et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 2004;127:1085-100. (Pubitemid 38623044)
90. Overell JR, Hsieh ST, Odaka M, et al. Treatment for Fisher syndrome, Bickerstaffs brainstem encephalitis and related disorders. Cochrane Database Syst Rev 2007:CD004761
91. Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology 2007;68:1144-6 (Pubitemid 46559850)
92. Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2010;6:CD002063
93. Ruts L, Drenthen J, Jacobs BC, van Doorn PA. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 2010;74:1680-6
94. Yuki N, Kuwabara S. Axonal Guillain-Barre syndrome: carbohydrate mimicry and pathophysiology. J Peripher Nerv Syst 2007;12:238-49 (Pubitemid 350179489)
95. Phongsisay V, Susuki K, Matsuno K, et al. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barre syndrome. J Neuroimmunol 2008;205:101-4
96. Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008;131:1197-208
97. van Koningsveld R, Steyerberg EW, Hughes RAC, et al. A clinical prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol 2007;6:589-94 (Pubitemid 46921042)